Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2 ‐Positive Metastatic Breast Cancer: A Single‐Center Pooled Analysis
Thoracic Cancer · 2026-08 · 17 (15)
DOI: 10.1111/1759-7714.70362 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 06.08.2026. Verfasst von Jialin Lin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijin…. Hauptthemen laut MEDLINE: Capecitabine, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National High Level Hospital Clinical Research Funding, Noncommunicable Chronic Disease-National Science and Technology Major Project, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Phase II and III trials have demonstrated progression‐free survival (PFS) benefits of pyrotinib plus capecitabine over lapatinib plus capecitabine in HER2‐positive metastatic breast cancer (MBC). However, long‐term overall survival (OS) data from a single‐center cohort remain limited. This pooled analysis compared OS between the two regimens and explored outcomes across prespecified subgroups.
Methods
We included patients with HER2‐positive MBC from our center enrolled in a Phase Ic study, a Phase II study, or the Phase III PHOEBE trial. The primary endpoint was OS. OS was analyzed using Kaplan–Meier estimates, log‐rank tests, and a multivariable Cox model adjusted for ECOG performance status, pathological grade, prior anti‐HER2 therapy, trastuzumab exposure duration, trastuzumab resistance, and prior chemotherapy lines. The proportional hazards assumption was assessed using Schoenfeld residuals. Exploratory subgroup analyses used prespecified categories.
Results
At data cutoff, 82 patients were included; 53 received pyrotinib plus capecitabine and 29 received lapatinib plus capecitabine. Baseline characteristics were comparable between groups. Median OS was 74.61 months (95% CI 41.10–not reached) with pyrotinib plus capecitabine and 30.98 months (26.12–50.76) with lapatinib plus capecitabine (log‐rank p = 0.0053). Cox models suggested a reduced risk of death with pyrotinib plus capecitabine. Subgroup analyses were exploratory and should be interpreted cautiously because several subgroup estimates were imprecise.
Conclusion
In this single‐center pooled analysis, pyrotinib plus capecitabine was associated with significantly longer OS than lapatinib plus capecitabine in patients with HER2‐positive MBC. These exploratory results are consistent with prior Phase II/III trials and provide evidence supporting the OS benefit of pyrotinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Beijing Key Laboratory of Innovative Drug R&D and Translational Research for Breast Cancer, Beijing, China.
ORCID-Profile: Jialin Lin, Qiao Li, Pin Zhang, Bo Lan, Jiani Wang, Hongnan Mo, Jiayu Wang, Binghe Xu
Förderung
- National High Level Hospital Clinical Research Funding
- Noncommunicable Chronic Disease-National Science and Technology Major Project
- National Natural Science Foundation of China
Zitieren
APA
Lin, J., Li, Q., Zhang, P., Fan, Y., Cai, R., Luo, Y., Lan, B., Chen, S., Wang, J., Mo, H., Ma, F., Wang, J., & Xu, B. (2026). Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2 ‐Positive Metastatic Breast Cancer: A Single‐Center Pooled Analysis. Thoracic Cancer, 17(15). https://doi.org/10.1111/1759-7714.70362
Vancouver
Lin J, Li Q, Zhang P, Fan Y, Cai R, Luo Y, et al. Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2 ‐Positive Metastatic Breast Cancer: A Single‐Center Pooled Analysis. Thoracic Cancer. 2026;17(15). doi:10.1111/1759-7714.70362
BibTeX
@article{Lin2026,
author = {Lin, Jialin and Li, Qiao and Zhang, Pin and Fan, Ying and Cai, Ruigang and Luo, Yang and Lan, Bo and Chen, Shanshan and Wang, Jiani and Mo, Hongnan and Ma, Fei and Wang, Jiayu and Xu, Binghe},
title = {Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2 ‐Positive Metastatic Breast Cancer: A Single‐Center Pooled Analysis},
journal = {Thoracic Cancer},
year = {2026},
volume = {17},
number = {15},
doi = {10.1111/1759-7714.70362}
}
EUVIMED